Liraglutide in Adults 65 and Older: Managing the Transition from Geriatric to Adult Care

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

Do the labels dose liraglutide differently at 65?

Both products are once-daily subcutaneous injections of liraglutide, given in the abdomen, thigh or upper arm at any time of day without regard to meals [1][2]. The dosing sections set one adult schedule each.

Saxenda starts at 0.6 mg daily for one week, then rises weekly to 1.2 mg, 1.8 mg, 2.4 mg, and 3 mg from week 5; lower doses are for titration only, and the label says to discontinue if 3 mg is not tolerated [1]. If a dose is not tolerated during escalation, the label says to consider delaying escalation by about one additional week [1].

Victoza starts at 0.6 mg daily for one week — a dose the label states is not effective for glycemic control in adults — then 1.2 mg, with 1.8 mg as the maximum if more glycemic control is needed after at least a week at 1.2 mg [2].

Neither dosing section lists an age-65 variation [1][2].

How much of the evidence comes from older adults?

Saxenda's five placebo-controlled adult trials enrolled 3,384 patients on liraglutide and 1,941 on placebo, and the mean age was 47 years [1]. Reviews of the field are blunt about the gap: a 2016 review of liraglutide 3.0 mg for weight management concluded that data in the geriatric population are limited [3], and a 2024 review of obesity pharmacotherapy in adults 65 and older found no concise guidelines for this age group and called for trials with geriatric endpoints such as muscle mass preservation and bone quality [4]. On the diabetes side, a 2011 review noted that 42% of the US population with diabetes is 65 or older while most noninsulin treatments had been studied only in people younger than 65 [5].

Victoza or Saxenda: the handoff item that matters most

The same drug name covers two products with different indications and different ceiling doses.

• Victoza: type 2 diabetes, used with diet and exercise, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; maximum 1.8 mg daily; not approved for weight loss [2].
• Saxenda: weight management with a reduced-calorie diet and increased physical activity, in adults with obesity or with overweight plus at least one weight-related comorbid condition, and in patients 12 and older weighing more than 60 kg with obesity; 3 mg daily [1].

Both labels state that coadministration with other liraglutide-containing products is not recommended [1][2]. A transition note that says only 'liraglutide' or only 'liraglutide 3 mg' leaves the receiving team to work out the product, and with it the indication, the titration ceiling and the monitoring that goes with it.

Saxenda also carries a dated requirement that a handoff can lose: for adults, the label directs evaluating weight change 16 weeks after starting and discontinuing if the patient has not lost at least 4% of baseline body weight [1]. A receiving adult-care team that does not know the start date cannot apply that checkpoint.

An interrupted schedule: the more-than-3-days rule

Both labels address an interrupted schedule, such as a gap during a hospital stay. For Saxenda, if more than 3 days have passed since the last dose, the label says to restart at 0.6 mg daily and follow its dose-escalation schedule again to reduce the risk of gastrointestinal adverse reactions [1]. For Victoza, the label says to restart at 0.6 mg daily, and after reinitiation Victoza should be titrated at the discretion of the healthcare provider [2]. For an ordinary missed dose, both labels say to resume the next scheduled dose and not to administer an extra dose to make up for it [1][2].

So the dose a patient returns on can differ from the dose in the geriatric team's last note: someone stable at 3 mg of Saxenda who has been off for more than 3 days restarts at 0.6 mg and goes through the escalation schedule again, and someone on Victoza restarts at 0.6 mg with the next steps left to the provider [1][2].

Sulfonylureas and insulin: the dose change that must travel

Both labels warn that hypoglycemia risk rises when liraglutide is combined with an insulin secretagogue such as a sulfonylurea, or with insulin, and both say the risk may be lowered by reducing the dose of those drugs [1][2].

The Saxenda label quantifies it. In the trial of adults with type 2 diabetes and overweight or obesity, among patients taking a sulfonylurea, plasma glucose below 54 mg/dL with or without symptoms occurred in 31 of 110 liraglutide-treated patients (28.2%) versus 7 of 55 on placebo (12.7%); sulfonylurea doses were reduced by 50% at the start of that trial per protocol [1]. In the Victoza glycemic-control trials, hypoglycemia requiring another person's assistance occurred in 8 liraglutide-treated patients (7.5 events per 1,000 patient-years), and 7 of those 8 were also taking a sulfonylurea [2].

If a geriatric prescriber reduced a sulfonylurea or insulin dose when liraglutide started, the handoff needs to say so, because dose reduction is the labels' stated way to lower that hypoglycemia risk [1][2].

What the labels say to watch after the transfer

Stomach and gut. In the Saxenda adult trials, nausea occurred in 39.3% versus 13.8% on placebo, diarrhea in 20.9% versus 9.9%, constipation in 19.4% versus 8.5% and vomiting in 15.7% versus 3.9%; 9.8% versus 4.3% discontinued because of adverse reactions [1]. In the Victoza trials, nausea occurred in 20% of patients receiving 1.8 mg and 5% of those receiving placebo [2]. Severe gastrointestinal reactions are a labeled warning for both products, and neither is recommended in patients with severe gastroparesis [1][2].

Kidneys. Both labels warn about acute kidney injury from volume depletion and say to monitor renal function in patients reporting reactions that could lead to volume depletion; the Victoza label adds especially during dosage initiation and escalation [1][2].

Heart rate. The Saxenda label reports a mean resting heart rate rise of 2 to 3 bpm, a rise of more than 10 bpm at two consecutive visits in 34% versus 19% on placebo, and at least one resting rate above 100 bpm in 6% versus 4%; the label instructs monitoring heart rate at regular intervals [1].

Gallbladder and pancreas. Cholelithiasis was reported in 2.2% versus 0.8% and cholecystitis in 0.8% versus 0.4% in the Saxenda adult trials, and both labels say to discontinue if pancreatitis is suspected [1][2].

Procedures. Both labels warn about pulmonary aspiration during general anesthesia or deep sedation and instruct patients to inform healthcare providers about planned surgeries or procedures [1][2].

Thyroid. Both products carry a boxed warning about thyroid C-cell tumors in rats and mice at clinically relevant exposures, with human relevance unknown, and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 [1][2].

The suicidal-thoughts warning is no longer in the Saxenda label

An older transition summary may still list 'monitor for depression or suicidal thoughts' as a Saxenda warning; the label dated 2024-01-26 did carry that section [6]. On 2026-01-13 FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the suicidal ideation and behavior language after a review that included a meta-analysis of 91 placebo-controlled GLP-1 receptor agonist trials (107,910 patients) and a claims cohort of 2,243,138 new users, finding no increased risk [7]. The Saxenda label effective 2026-02-25 no longer contains that warning [1].

Generic liraglutide at a handoff

FDA-approved generic liraglutide exists, including products referencing Saxenda and products referencing Victoza [8]. At a handoff, the product name on the pharmacy label is the detail that matters, because a generic referencing Victoza is for type 2 diabetes and a generic referencing Saxenda is for weight management [8].

A handoff checklist built from the labels

• Product name — Victoza or Saxenda — and the current dose in mg [1][2]
• Titration position: Saxenda week 1 through 5, or Victoza at 0.6, 1.2 or 1.8 mg [1][2]
• Date of the last dose, and whether more than 3 days have passed [1][2]
• Any sulfonylurea or insulin dose reduced when liraglutide started [1][2]
• Most recent renal function, and any recent vomiting or diarrhea [1][2]
• For Saxenda, the start date and whether the 16-week weight check has been done [1]
• Any planned surgery or procedure involving sedation [1][2]
• Any older note that still lists a suicidal thoughts warning for Saxenda [1][6]